Effect of Trifluoperazine in treatment of COVID-19

INTERVENTION: Intervention 1: Intervention group:35 participants in the investigational treatment group will receive trifluoprazine at a dose of 5 mg twice daily for 14 days on admission in addition to standard treatment consisting of hydroxychloroquine. If necessary, according to the approved treatment protocol, kaletra and ribavirin would be added to the treatment. Intervention 2: Control group:35 participants in control group, would receive standard treatment protocol consisting hydroxychloroquine and , if necessary, according to the approved treatment protocol, kaletra and ribavirin would be added to the treatment. CONDITION: COVID‐19 disease. ; Pneumonia due to SARS‐associated coronavirus U07.1 PRIMARY OUTCOME: Determining the efficacy of trifluoprazine in improving the Clinical manifestations of patients with confirmed COVID‐19 infection by recording the patient's clinical parameters including 7 clinical parameters of respiration number, Blood Oxigen Saturation, oxygen support, temperature, heart rate, systolic blood pressure and Awareness level, assessment of lung involvement with Chest CT‐Scan, measurement of c‐reactive protein on treatment days, measurement of CBC indicators and biochemical factors such as urea and creatinine. Timepoint: Check of the patient's clinical condition and blood sampling of patients on days 1‐14 in the hospital and also on the 28th day after the onset of the disease. Method of measurement: Measuring CBC indicators and biochemical factors using an autoanalyzer and examining heart function using EKG,Measurement of other factors using a thermometer and blood pressure monitor and patient bedside examinations. INCLUSION CRITERIA: Patients with laboratory‐confirmed COVID 19 infection with Real Time PCR and patients with evidence of lung involvement in CT Scan Willing to provide informed consent Age older than 12 years. Patients admitted to specialized COVID‐19 ward Patients without Known severe allergy to trifluoperazine perazin and other phenothiazines such as cholorphenothiazines Patients older than age 65 years are included if they do not suffer from Dementia‐Related Psychosis